Home › Funds › Nicholas Investment Partners, LP › XENE

Nicholas Investment Partners, LP position in XENE

XENON PHARMACEUTICALS INC · Health Care

Nicholas Investment Partners, LP reported holding 395,844 shares of XENE (XENON PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$23.9M, representing 1.50% of its reported portfolio and ranking #10 among its reported holdings. Nicholas Investment Partners, LP has disclosed XENE holdings in 11 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)395.84K sh
Reported value held$23.89M
Portfolio Weight1.50%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Nicholas Investment Partners, LP's XENE position evolved

Nicholas Investment Partners, LP first disclosed a stake in XENE in Q3 2023 at 854,447 shares (US$29.2M). Across 11 filings, Nicholas Investment Partners, LP increased the stake 6 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 395,844 shares valued at US$23.9M — an increase of 148,743 shares quarter over quarter.. Notable position changes include a 91% increase in Q1 2024 (shares fell 9% over the following quarter), a 493% increase in Q1 2025 (shares fell 7% over the following quarter), a 104% increase in Q4 2025 (shares rose 30% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 854.45K $29.19M New
Q4 2023 87.75K $4.04M Reduce
Q1 2024 167.93K $7.23M Add
Q3 2024 14.66K $577.09K New
Q4 2024 14.66K $574.59K Hold
Q1 2025 86.97K $2.92M Add
Q2 2025 68.90K $2.16M Reduce
Q3 2025 119.10K $4.78M Add
Q4 2025 242.99K $10.89M Add
Q1 2026 247.10K $14.37M Add
Q2 2026 395.84K $23.89M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XENE and 13F data

XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 44 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$348.7M), Polar Capital Holdings Plc (US$275.9M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$266.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XENE

All XENE fund holders →

FAQ

How long has Nicholas Investment Partners, LP held XENE?

Nicholas Investment Partners, LP has disclosed XENE holdings in 11 of the last 12 reported quarters, going back to Q3 2023.

What is Nicholas Investment Partners, LP's current position in XENE?

As of Q2 2026, Nicholas Investment Partners, LP holds 395.84K shares of XENE (XENON PHARMACEUTICALS INC), valued at $23.89M, representing 1.50% of its reported portfolio and ranking #10.

Has Nicholas Investment Partners, LP been buying or selling XENE?

In the latest 13F filing (Q2 2026), Nicholas Investment Partners, LP increased its position in XENE.

Which other funds hold XENE?

Other major institutional holders of XENE include Avoro Capital Advisors LLC, Polar Capital Holdings Plc, DRIEHAUS CAPITAL MANAGEMENT LLC, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.